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Background. The natural history of autosomal-dominant
polycystic kidney disease (ADPKD) has not been well de-
scribed in children and infants.
Methods. The present study analyzed the characteristics of 46
ADPKD children diagnosed before 18 months of life (VEO)
and 153 children diagnosed between 18 months of age and
18 years of age (non-VEO).
Results. VEO children had more cysts and larger renal vol-
umes than non-VEO children when adjusted for age. In both
VEO and non-VEO children, the presence of signs or symptoms
at the time of diagnosis as well as the presence of hematuria or
proteinuria at the study visit were associated with larger renal
volumes. Children diagnosed early (VEO) or diagnosed due
to signs or symptoms were also more likely to have high blood
pressure. Two VEO children and no non-VEO children reached
end-stage renal disease during follow-up.
Conclusion. In contrast to many published case reports sug-
gesting the occurrence of early end-stage renal disease in VEO
children, the results of the present study were much more op-
timistic. Over 90% of the VEO children maintained preserved
renal function well into childhood.
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most frequent life-threatening hered-
itary disease [1], affecting from 1 in 500 to 1 in 1000
individuals in the United States and Europe. It accounts
for 4.4% of end-stage renal disease (ESRD) in the
United States [2]. Although ADPKD often is considered
a disease of adults, it is clear that the disease begins in
childhood. Renal cysts in children with ADPKD have
been associated with wide clinical spectra, ranging from
totally asymptomatic patients to those who present as
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newborns with massive renal enlargement, hypertension,
oliguria, and pulmonary hypoplasia [3]. While many case
reports of symptomatic, severe disease in early childhood
have been published [4, 5], very few cross-sectional [6]
and longitudinal studies [7] have been performed on
the rate of progression and the factors associated with
progression in children.
In adults, factors other than the culprit gene mutation
alone contribute to the course of progression of the re-
nal failure. The following variables have been indepen-
dently associated with progression to ESRD: the PKD1
compared to the PKD2 gene mutation, younger age at
diagnosis, male gender, hypertension, increased left ven-
tricular mass, hepatic cysts in women, three or more preg-
nancies, gross hematuria, urinary tract infections in men,
and renal size expressed as renal volume [8]. However,
disease progression and outcome have not been fully un-
derstood in the patients who are diagnosed in the early
months of life.
Given the frequency of ADPKD in the population and
the widespread use of imaging techniques in pregnancy,
it is likely that more fetuses and young children will be
identified with ADPKD. In the previous case reports the
ADPKD patients who have been diagnosed in fetal life
or infancy were considered to have a high rate of mor-
tality and severe complications [9–11]. The number of
ADPKD subjects in these reports, however, was small
and the duration of follow-up brief. We therefore under-
took a comprehensive prospective analysis of the natural
history of 46 ADPKD children who were diagnosed ei-
ther in utero or within the first 18 months of life [i.e., very
early onset (VEO)], and 153 ADPKD children who were
diagnosed between 18 months and 18 years of age.
METHODS
Since 1985, 895 subjects with ADPKD from 419 fami-
lies participated in ADPKD studies at the University of
Colorado Health Sciences Center (UCHSC). All parents
were asked to have their children participate in an ongo-
ing longitudinal study. In addition, children with known
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ADPKD were referred to the UCHSC for participation
in the study. The children and their affected parent were
asked to return for follow-up visits every three years. Par-
ents provided informed consent, and all children over the
age of seven years provided an assent.
All children and their affected parent were admitted
to the Pediatric Clinical Research Center at The Chil-
dren’s Hospital or to the General Clinical Research Cen-
ter at University Hospital in Denver for a 48-hour stay.
All children and parents underwent a standard history,
physical examination, blood sampling for complete blood
count, routine chemistries and gene linkage analysis, and
collected 24-hour urine specimens for creatinine, elec-
trolytes, and protein as previously described [12].
Blood and urinary chemistry determinations were
performed by the Clinical Laboratories of University
Hospital or The Children’s Hospital. Urinary protein
concentrations were measured using the Coumassie blue
dye-binding method [13]; urinary albumin concentra-
tions were measured since 1994 using a standard ra-
dioimmunoassay (Diagnostics Products, Los Angeles,
CA, USA). Overt proteinuria was defined as urinary
protein excretion greater than 4 mg/m2 per hour [14].
Glomerular filtration rate (GFR) was calculated by the
Schwartz formula GFR = (k×L)/PCr, where L is the
length (height) of the child in cm, PCr the plasma cre-
atinine concentration in mg/dL, and k = 0.45 for children
younger than two years, k = 0.55 for children age 2 to
12 years and for girls age 13 to 18 years, and k = 0.70 for
boys age 13 to 18 years old [15].
During their two-day hospital stay, the children had
multiple blood pressure measurements obtained (mean
14, range 2 to 20); these were taken on the dominant
arm with an automatic device (Dynamap; Critikon, Inc.,
Tampa, FL, USA) in the sitting position using a cuff ap-
propriate for the child’s upper arm circumference. These
blood pressures were compared with established stan-
dards of blood pressures for children of a given age, gen-
der, and height [16]. Hypertension was defined as 50% or
more of either systolic or diastolic in-house blood pres-
sures above the 95th percentile for age-, gender-, and
height-matched children, or being on antihypertensive
therapy, whereas normal blood pressure was defined as
more than 50% of both systolic and diastolic blood pres-
sures at or below the 95th percentile.
All children had abdominal ultrasonography as pre-
viously described [17]. Abdominal ultrasound was per-
formed with a high-resolution real-time scanner (Acuson
1.28 EXP with a 3.5 or 5.0 MHz transducer; Acuson,
Malvern, PA, USA). The children were considered to
have ADPKD if they had a family history and at least a
single cyst by ultrasonography. Renal cysts were counted,
if possible, or tabulated as 0, 1–5, 6–15, or greater than
15. The largest cyst in each kidney was reported, as well
as the predominant cyst size (<2 cm, 2–5 cm, or >5 cm)
and whether the cysts were uniform or variable in size.
Renal volume was calculated as a modified ellipse from
the measurements obtained by ultrasound [6]. Because in
this study only a small number of children had markedly
asymmetric kidneys, that is, one kidney having more than
double the volume of the other, the mean renal vol-
ume was calculated for each child as the average of the
two kidneys. Renal volumes were determined at every
visit (on average every 3 years) for all affected and un-
affected children. Echocardiograms were performed as
previously described [18]. Follow-up data on hyperten-
sion and ESRD were sought on all children by question-
naire or phone call between December 2004 and early
2005.
The data were analyzed using SAS (Statistical Analy-
sis System; Cary, NC, USA). Ages are presented as the
mean ± standard deviation. P values < 0.05 were consid-
ered significant; P values < 0.10 are reported. T tests were
used to compare means between groups. Age-adjustment
using analysis of covariance (ANCOVA) was performed
for all quantitative variables; age-adjusted data are pre-
sented as the least squares mean ± the standard er-
ror. Log transformations were used for renal growth
rate because of skewed distributions. Qualitative param-
eters were compared between groups using chi-square
analysis.
RESULTS
Forty-six subjects from 40 families were diagnosed with
ADPKD by imaging within the first 18 months of life.
Among them, 10 were diagnosed due to signs or symp-
toms, including the physical finding of an abdominal mass
(N = 8) or the symptom of acute pyelonephritis (N = 2).
The remaining 36 subjects were asymptomatic at the time
of diagnosis; they were diagnosed by renal ultrasound
screening in families with a history of ADPKD (N = 30,
14 were diagnosed in utero) or as an incidental finding
on a routine prenatal ultrasound (N = 6). One hundred
fifty-three subjects from 109 families were diagnosed by
imaging after age 18 months but before age 18 years (non-
VEO). Among them, 41 were diagnosed due to signs or
symptoms, including pain (N = 12), hypertension (N =
8), urinary tract infection (N = 6), hematuria (N = 7), kid-
ney stones (N = 2), frequency (N = 2), and one subject
each for abdominal mass, acute pyelonephritis, enuresis,
and stress incontinence. One hundred and seven non-
VEO children were diagnosed due to screening; for 5
non-VEO children the data on reason for diagnosis are
missing. Seventeen of the non-VEO children had nega-
tive renal ultrasounds prior to the ultrasound at which
they received the diagnosis, one child at age 14. All chil-
dren were born between 1975 and 1997. Fifteen families
had both a VEO and a non-VEO child.
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Table 1. Characteristics of VEO and non-VEO patients at last
clinical research center visit
VEO non-VEO
(N = 46) (N = 153) P value
Age at last visit years ± SD 9.5 ± 5.8 14.5 ± 4.3 <0.0001
Gender % male 46 46 NS
Affected mother % 67 58 NS
Serum creatinine mg/dLa 0.9 ± 0.05 0.8 ± 0.03 <0.005
Creatinine clearance
mL/min/1.73m2a
103 ± 4 116 ± 2 <0.005
Schwartz GFR
mL/min/1.73m2a
113 ± 4 129 ± 2 <0.005
Urinary protein excretion
mg/24 hra
192 ± 29 158 ± 13 NS
Overt proteinuria % 45 34 NS
Urinary osmolality
mOsm/kga
725 ± 50 858 ± 20 <0.05
Hypertensive % 43 29 0.06
Left ventricular mass index
g/m2a
77 ± 3 72 ± 1 0.07
Liver cyst(s) present on
ultrasound %
2 1 NS
History of inguinal hernia % 18 5 <0.01
History of umbilical hernia % 9 1 <0.05
Family history of intracranial
aneurysm %
24 32 NS
History of gross hematuria % 15 15 NS
aAge-adjusted mean ± SEM.
Characteristics of VEO versus non-VEO children
Table 1 shows the characteristics at the last clinical re-
search center visit of the VEO and non-VEO children.
The VEO patients were significantly younger. [Because
VEO patients were diagnosed in the early months of life,
they were also younger at their first visit (5.5 ± 5.4 vs.
10.4 ± 4.5 years, P < 0.0001)]. The VEO children had
higher serum creatinine concentrations, lower creatinine
clearance and GFR, lower overnight urinary osmolality,
and excreted more protein in their urine. The difference
in protein excretion, however, was not significant. Hy-
pertension was more prevalent and left ventricular mass
indices were greater in VEO subjects, although the dif-
ferences did not quite reach statistical significance. The
VEO patients had more hernias. Another finding was that
VEO patients, at comparable ages, had a higher percent-
age, with 20 or more renal cysts (P <0.05) (Fig. 1). Figure 2
depicts the age-adjusted renal volumes, which were larger
in the VEO than in the non-VEO children (370 ± 38 vs.
224 ± 20 cm3, P < 0.005). At their last visit, 54% of VEO
and 29% of non-VEO children had too many cysts to
count. The predominant cyst size was less than 2 cm in
over 90% of the children (both VEO and non-VEO), and
the cysts tended to be uniform in size. The largest cyst was
usually less than 3 cm (mean 2.7 cm, range 0.3–8.9 cm, in-
terquartile range 1.4–3.7 cm) and increased slowly over
time (<0.2 cm/year).
Diagnosis due to signs or symptoms versus screening
Clinical characteristics of both VEO and non-VEO
children who were diagnosed due to signs or symptoms
are compared with characteristics of children diagnosed
due to screening in Table 2. In both VEO and non-VEO
groups, children diagnosed due to signs or symptoms had
higher age-adjusted serum creatinine levels, lower age-
adjusted creatinine clearances and GFRs, and a greater
frequency of hypertension than children diagnosed due
to screening. Mean age-adjusted renal volumes of the
groups are shown in Figure 3.
Relationship between hematuria and proteinuria with
renal volume in ADPKD children
Both hematuria and overt proteinuria were associated
with larger renal volumes in both VEO and non-VEO
children (Fig. 4).
Hypertension and ESRD at follow-up
Comparisons between VEO and non-VEO children
at the most recent follow-up demonstrated significantly
more hypertension in the VEO than in the non-VEO
children (52% vs. 32%, P < 0.05), and between non-VEO
children diagnosed due to signs or symptoms versus non-
VEO children diagnosed due to screening (VEO 60% vs.
50%, P = NS; non-VEO 59% vs. 23%, P < 0.0001). ESRD
had occurred in only 2 of the 46 VEO children (4.3%,
at ages 3.5 and 4); the mean age of the VEO children
at follow-up was 13.4 ± 6.9 years (range 1 to 29 years).
None of the non-VEO children developed ESRD by a
mean age of 16.2 ± 5.2 years (range 2 to 27 years). The
two VEO children who reached ESRD were diagnosed
due to signs or symptoms (abdominal mass).
Increases in renal volume over time
Overall, renal volume growth rate increased with age
with the highest growth rate during puberty (age at first
visit 0 to <5 years: 8.7 ± 1.2 cm3/year; 5 to <10 years
16.8 ± 1.2 cm3/year; 10 to <15 years: 25.0 ± 1.2 cm3/year;
P < 0.0001). There was a near significant difference in
renal volume growth rate between VEO and non-VEO
children (age-adjusted mean ± SEM VEO 18.6 ± 1.2 vs.
non-VEO 12.7 ± 1.1, P = 0.06).
DISCUSSION
Over the past two decades, it has become clear that
ADPKD is a significant entity in childhood, and clinical
characteristics of ADPKD children have been reported
[5–7, 18]. The progression of ADPKD to ESRD and the
presence of other complications are highly variable in
children [6] and are not completely understood in the
early years of life. In the present study, 46 subjects from
40 families whose disease had been diagnosed within the
first 18 months of life (VEO) were evaluated and com-
pared with those children who were diagnosed between
18 months and 18 years of age (153 subjects).
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Fig. 1. A greater percentage of VEO chil-
dren had 20 or more renal cysts bilaterally
on ultrasound than non-VEO children at
the last clinical research center visit (overall
P < 0.05).
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Fig. 2. VEO children had larger (age-
adjusted) renal volumes than non-VEO chil-
dren at the last clinical research center visit.
Table 2. Characteristics of VEO and non-VEO patients, diagnosed due to signs or symptoms (SY) or diagnosed for screening (SC), at last clinical
research center visit
VEO SY VEO SC P value non-VEO SY non-VEO SC
(N = 10) (N = 36) VEO (N = 41) (N = 107) P value non-VEO
Age at last visit years ± SD 11.6 ± 6.1 8.9 ± 5.7 NS 15.2 ± 4.4 14.3 ± 4.1 NS
Gender % male 50 44 NS 39 48 NS
Affected mother % 60 69 NS 54 61 NS
Serum creatinine mg/dLa 1.3 ± 0.16 0.6 ± 0.08 <0.001 0.8 ± 0.04 0.8 ± 0.02 NS
Creatinine clearance mL/min/1.73m2a 93 ± 10 111 ± 6 NS 107 ± 3 119 ± 2 <0.005
Schwartz GFR mL/min/1.73m2a 96 ± 12 125 ± 6 <0.05 118 ± 4 131 ± 2 <0.01
Urinary protein excretion mg/24 hra 219 ± 68 141 ± 39 NS 164 ± 25 166 ± 15 NS
Overt proteinuria % 50 43 NS 42 32 NS
Urinary osmolality mOsm/kga 799 ± 143 730 ± 63 NS 850 ± 52 863 ± 21 NS
Hypertensive % 60 39 NS 59 19 <0.0001
Left ventricular mass index g/m2a 80 ± 5 72 ± 12 NS 74 ± 3 72 ± 2 NS
Liver cyst(s) present on ultrasound % 0 3 NS 5 0 <0.05
History of inguinal hernia % 33 14 NS 7 5 NS
History of umbilical hernia % 20 6 NS 2 1 NS
Family history of intracranial aneurysm % 25 24 NS 22 36 NS
History of gross hematuria % 30 11 NS 39 6 <0.0001
aAge-adjusted mean ± SEM.
In adults, several risk factors for faster progression
have been identified, including the PKD1 gene, male
gender, a younger age at diagnosis, the presence of hy-
pertension, hematuria, and proteinuria, a younger age at
onset of hypertension and hematuria, larger kidneys, and
a younger age at incipient renal failure [7, 19–21]. How-
ever, disease progression and outcome have not been
completely described in a large series of VEO-ADPKD
patients. Because the disease begins in childhood, identi-
fying risk factors and the disease course in the early years
of life might provide the greatest potential for effective
intervention in high-risk patients.
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Fig. 3. At the last clinical research center visit, both VEO and non-
VEO ADPKD children diagnosed due to signs or symptoms (SY) had
larger (age-adjusted) renal volumes than ADPKD children diagnosed
due to screening (SC).
The VEO-ADPKD patients had larger kidney size
and a greater frequency of hypertension than non-VEO
ADPKD children. This relationship between larger kid-
neys and more hypertension has been associated with
the up-regulation of the intrarenal renin-angiotensin-
aldosterone system (RAAS). Renin has been found to
be overexpressed in polycystic kidneys [22]. It has been
observed in high concentrations in cyst fluid, and the cyst
epithelia have the ability to synthesize renin [23]. These
observations with renal renin could lead to excess an-
giotensin II production in children with larger kidneys
and more cysts, thus contributing to higher blood pres-
sures. Moreover, angiotensin II is a growth factor for re-
nal tubular cells and enhances the mitogenic actions of
epidermal growth factor (EGF); thus, angiotensin II may
contribute to a faster renal growth rate in hypertensive
children with enlarged kidneys [24].
Renal enlargement is a marker for disease progres-
sion and renal volume may be a useful marker for dis-
ease progression in early stages of ADPKD when GFR
is preserved [25]. In this regard, structural progression
in terms of increased cyst numbers and kidney size was
shown to be greater in VEO patients compared to non-
VEO children, and in children who were diagnosed due
to symptoms compared with children diagnosed due to
screening. Because many of the children had too many
cysts to count, it was necessary to use renal volume rather
than cyst number for comparisons.
Both VEO and non-VEO ADPKD children with pro-
teinuria had larger renal volumes than those without pro-
teinuria. This finding is similar to that observed in adults
with ADPKD. In adults, increased proteinuria is associ-
ated with faster progression of renal disease [21], and the
present results in ADPKD children are also compatible
with this interpretation.
Gross hematuria has been described as a risk factor for
faster progression in ADPKD adults [26]. Hematuria is
not common in children with ADPKD (15%) but in the
present study both VEO and non-VEO ADPKD chil-
dren with a history of hematuria had larger kidneys. Thus,
hematuria may be associated with increased rate of pro-
gression in both children and adults. Renal stones as a
cause of hematuria are very rare in ADPKD children
[26].
To further assess the outcome and progression of
ADPKD in childhood, the same risk factors were com-
pared between ADPKD children who were diagnosed
due to symptoms with those who were diagnosed for
screening. The results demonstrate that both VEO and
non-VEO ADPKD children diagnosed due to symptoms
had decreased renal function as measured by serum cre-
atinine, creatinine clearance, and estimated GFR. Renal
volumes were also greater in children diagnosed due to
symptoms. This was true even though some of the symp-
toms may not have been specifically related to ADPKD
(such as urinary tract infection, which was a reason for
diagnosis in 6 non-VEO children, all girls). At last follow-
up, two VEO children who had been diagnosed due to
symptoms (abdominal mass) had reached ESRD and
none of the non-VEO had ESRD.
In the present study of infants and children with
ADPKD the outcomes were better than in most previ-
ous reports. MacDermot et al analyzed ADPKD studies
of 83 case reports presenting in utero or in the first few
months of life. The reported mortality was 43% (36/83)
in the first year of life [27]. This difference in outcomes
from the current report may be related to a bias for VEO
children with more severe disease to be published in case
report studies. In the present study the children were all
seen at the clinical research center, which may present
a bias against more severely affected children. However,
when the pedigrees were searched for affected children
not studied here, there were no additional VEO children
born between 1975 and 1997 who had reached ESRD.
One VEO child born before 1975 reached ESRD at age
17; this child’s family has been described in several other
reports [28–30].
CONCLUSION
VEO children have worse age-adjusted renal function,
larger renal volumes, more hypertension, and increased
left ventricular mass index compared with non-VEO
children. Proteinuria, hematuria, and signs/symptoms at
diagnosis are associated with larger age-adjusted renal
volumes in both VEO and non-VEO children. Over 90%
of VEO children maintained preserved renal function
well into childhood. Because larger kidneys are associ-
ated with increased morbidity and more rapid progres-
sion to ESRD, the potential for reducing renal growth
and left ventricular mass by blockade of the RAAS and
reduction in blood pressure level should be studied as a
potential therapeutic goal starting in childhood [24]. Such
a prospective, randomized study in ADPKD children
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Fig. 4. Both VEO and non-VEO ADPKD
children with (A) proteinuria or (B) hema-
turia had larger (age-adjusted) renal volumes
than ADPKD children without these mani-
festations at the last clinical research center
visit.
is underway at the UCHSC. Moreover, in counseling par-
ents of a VEO child, the present results suggest that
the physician can indicate the likelihood that reason-
able kidney function will be maintained during childhood
and adolescence. However, these children should be fre-
quently monitored for complications such as hyperten-
sion and renal insufficiency.
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